Business development decisions have started the clock on a financial time bomb set to go off within the next three months.
Targeting a mechanism of resistance to first-generation BTK inhibitors has caught the attention of biotechs like Arqule, which claimed a major success last week.
Fears about flattening Opdivo sales were surely a major driver for Bristol's move for Celgene. To keep growing the checkpoint inhibitor needs some big clinical wins.
Three gene therapy contenders, Abeona, Fibrocell and Krystal, are taking different approaches in the quest to cure epidermolysis bullosa.
The J&J-Auris tie-up will yield a huge return for investors who went in big.
Curevac’s decision to exit work on an mRNA approach to OTC deficiency follows a clinical hold on Translate Bio’s similar project, and raises broader concerns.
As Gilead bows out of BCMA, Novartis pins its hopes on a BCMA/CD19 combo.
An upcoming Icer report will put the spotlight on unjustified price increases even as signs of moderation emerge.
At a time when most of biotech seems to want to become “the next Genentech” Array Biopharma has stuck to a partnering model and, in hindsight, lost out in the process.